Negative in Ames and in vivo micronucleus; positive in vitro micronucleus (24-hour); overall non-genotoxic
“Oveporexton was found to be negative in an Ames assay and in an in vivo micronucleus assay; however, it was found to be positive for induction of micronuclei in an in vitro micronucleus assay following 24-hours of continuous treatment. Overall oveporexton was determined to be non-genotoxic.”
✓ VerifiedFDA multi-discipline review, p. 48Source ↗
Carcinogenicity
2-year rat and 6-month transgenic mouse: not carcinogenic
“Oveporexton was also found to be non-carcinogenic in a GLP 2-year rat and a GLP 6-month transgenic mouse carcinogenicity study.”
✓ VerifiedFDA multi-discipline review, p. 48Source ↗
Reproductive & developmental
Rat and rabbit EFD: no drug-related malformations or embryo-fetal lethality
“There were no drug-related effects on the incidence of congenital malformations or embryo-fetal lethality in either rats or rabbits.”
✓ VerifiedFDA multi-discipline review, p. 48Source ↗
Safety pharmacology
Rats: CNS (body temperature changes, hyperactivity at ≥20 mg/kg) and respiratory effects; monkeys: increased blood pressure and LV pressure at ≥3 mg/kg
“Results from GLP-compliant safety pharmacology studies indicated that oveporexton can affect the CNS (increased body temperature at 20 and 100 mg/kg, decreased body temperature at 1000 mg/kg, and hyperactivity at ≥20 mg/kg in rats), the cardiovascular system (increased blood pressure and left ventricular pressure at ≥3 mg/kg in monkeys), and the respiratory system”
✓ VerifiedFDA multi-discipline review, p. 46Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative